MetaCap

Liquidia (LQDA) vs Veradermics (MANE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Veradermics is the larger company by market cap ($5.04 billion vs $4.90 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LQDA+22.51%MANE+216.61%
+333%+137%-60%
Feb 4, 20261 yearNov 20, 2026
LQDA+26.46%MANE+210.60%
+278%+113%-51%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LQDA versus MANE key metrics
MetricLQDAMANE
Share price$54.43$119.52
Market cap$4.90B$5.04B
1-day change-3.88%-3.92%
YTD return+57.81%—
1-year return+86.98%—
5-year return+1224.33%—
Forward P/E15.12—
EPS (TTM)$-1.05$-3.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$158.32M—
Revenue growth (YoY)+1031.18%—
Net income (latest FY)$-68.92M$-70.00M
Operating margin-32.45%—
Net margin-43.53%—
52-week high$93.61$156.63
52-week low$22.31$32.00
Distance from 52-week high-41.85%-23.69%
Analyst consensusbuystrong_buy
Avg. price target upside+21.50%+56.74%
Average volume3.52M738.22K
Shares outstanding90.11M42.20M
Employees21651
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

About Veradermics

MANE stock →

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

LQDA vs MANE FAQ

Which is bigger, Liquidia or Veradermics?

Veradermics (MANE) is larger, with a market capitalization of $5.04B compared with $4.90B for Liquidia (LQDA).

Are Liquidia and Veradermics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons